⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 4, 2024Open Access

Table S8 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study

Tero Sievänen Tiina Jokela Matti Hyvärinen Tia‐Marje Korhonen Kirsi Pylvänäinen Jukka‐Pekka Mecklin Juha Karvanen Elina Sillanpää Toni T. Seppälä Eija K. Laakkonen

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Table S8: 5-fold cross-validated MLH1 c-miR risk sum score model.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sievänen et al. (2024) studied this question.

synapsesocial.com/papers/68e664bab6db6435875f132c https://doi.org/10.1158/1940-6207.25964382.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S5 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
2Table S11 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
3Table S11 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
4Table S6 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
5Table S6 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024

Figure S1 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
Table S12 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024
Table S12 from Circulating miRNA Signature Predicts Cancer Incidence in Lynch Syndrome—A Pilot Study2024